title: How important is preventing platelet activation in the setting of percutaneous coronary intervention?
abstract: The benefit of antithrombotic therapies is exerted primarily through inhibition of platelet activation and not solely through platelet aggregation. Inhibition of platelet activation can influence localized inflammatory processes as well as long-term clinical outcome. The combination of aspirin, adequate platelet inhibition with P2Y12-receptor inhibitors and thrombin inhibition can synergistically inhibit platelet activation, and the use of this combination may have important clinical implications for treatment of patients undergoing percutaneous coronary intervention.
authors.affiliation: Linda and Jack Gill Cardiovascular Institute, University of Kentucky, Lexington, Kentucky, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Steinhubl
mesh_terms: D000818:Animals; D000077144:Clopidogrel; D004357:Drug Synergism; D006801:Humans; D062645:Percutaneous Coronary Intervention; D015539:Platelet Activation / Q000502:physiology*; D010974:Platelet Aggregation / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D018179:Receptors, Thrombin / Q000502:physiology; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D018179:Receptors, Thrombin; D000077144:Clopidogrel; D013988:Ticlopidine